SCIENTIFIC HUB

Follow the evidence.

15.306 articles found

Source record

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Welch J, Duncan G, Power K, Gallen S, Kerr J, Chaudhuri KR, Batzu L, Rota S, Jabbari E, Morris H, Limousin P, Greig N, Li Y, Libri V, Gandhi S, Athauda D, Chowdhury K, Foltynie T.

Lancet · 2025-02-04

DOI: 10.1016/s0140-6736(24)02808-3PMID: 39919773

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Open access

Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson’s disease

Tan MM, Iwaki H, Bandres-Ciga S, Sosero Y, Shoai M, Brockmann K, Williams NM, Alcalay RN, Maple-Grødem J, Alves G, Tysnes O, Auinger P, Eberly S, Heutink P, Simon DK, Kieburtz K, Hardy J, Williams-Gray CH, Grosset DG, Corvol J, Gan-Or Z, Toft M, Pihlstrøm L.

· 2025-02-03

DOI: 10.1101/2025.01.31.25321395

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Open access

Exploring how PRIME-Parkinson care is implemented and whether, how and why it produces change, for who and under what conditions: a protocol for an embedded process evaluation within the PRIME-UK randomised controlled trial.

Lloyd K, Tenison E, Smith S, Lithander F, Kidger J, Brant H, Redwood S, Ben-Shlomo Y, Henderson EJ.

BMJ Open · 2025-02-02

DOI: 10.1136/bmjopen-2024-086353PMID: 39894518

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Source record

Skin adhesion of a newly developed, bioequivalent rotigotine patch formulation in comparison to the originator product: Results of a multi-center, randomized, crossover trial in patients with Parkinson's disease.

Jost WH, Wang M, Wauer G, Dax A, Wedemeyer RS, Schug B, Warnke A, Leblanc A, Schurad B.

Int J Clin Pharmacol Ther · 2025-02-01

DOI: 10.5414/cp204672PMID: 39370808

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.
Open access

An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.

Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA.

JAMA Neurol · 2025-02-01

DOI: 10.1001/jamaneurol.2024.4519PMID: 39761063

A bibliographic record traceable to Europe PMC. Türkçe başlık: makine çevirisi, editoryal kontrol bekliyor.

Records come from scientific sources. Bibliographic counts do not represent completed translations or editorial approvals.

Filters

Filters

Clear
Publication year
Research area
Author
Journal
Publication type
Source & language
Open accessAccess does not establish reuse rights.